S1326
SB−3CT
≥98% (HPLC), matrix metalloproteinase MMP-2 and MMP-9 inhibitor, powder
Synonym(s):
2-[[(4-phenoxyphenyl)sulfonyl]methyl]-Thiirane
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C15H14O3S2
CAS Number:
Molecular Weight:
306.40
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Product Name
SB−3CT, ≥98% (HPLC), powder
Quality Level
Assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to off-white
solubility
DMSO: >20 mg/mL
storage temp.
−20°C
SMILES string
O=S(=O)(CC1CS1)c2ccc(Oc3ccccc3)cc2
InChI
1S/C15H14O3S2/c16-20(17,11-14-10-19-14)15-8-6-13(7-9-15)18-12-4-2-1-3-5-12/h1-9,14H,10-11H2
InChI key
LSONWRHLFZYHIN-UHFFFAOYSA-N
Related Categories
Application
SB−3CT has been used as irreversible inhibitor of matrix metallopeptidase 9 (MMP9) in cell cultures to exclude reciprocal regulation.
Biochem/physiol Actions
SB−3CT is a potent matrix metalloproteinase MMP-2 and MMP-9 inhibitor.
SB-3CT is a potent matrix metalloproteinase MMP-2 and MMP-9 inhibitor. Matrix metalloproteinases (MMPs) are involved in a number of activities including angiogenesis and embryogenesis. In particular, gelatinases A (MMP-2) and B (MMP-9), are thought to facilitate tumor metastasis. SB-3CT exhibits a covalent mechanism based behavior in inhibition of MMP-2 and MMP-9. This inhibitor appears to have similarity to TIMP-1 and TIMP-2 in the slow-binding component of inhibition. SB-3CT has been shown to directly bind to the zinc in the catalytic site of MMP-2. SB-3CT does not affect the activities of MMP-1 (Ki = 206 μM) MMP-3 (Ki = 15 μM), or MMP-7 (Ki = 96 μM).
Legal Information
Sold under license of U.S. Patent 6,703,415.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Chiara Sassoli et al.
Stem cells international, 2018, 5034679-5034679 (2018-05-02)
Bone marrow-derived mesenchymal stromal cell- (BM-MSC-) based therapy is a promising option for regenerative medicine. An important role in the control of the processes influencing the BM-MSC therapeutic efficacy, namely, extracellular matrix remodelling and proliferation and secretion ability, is played
Youqiong Ye et al.
Genome medicine, 12(1), 83-83 (2020-09-30)
Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit in several malignancies, but has shown favorable response in only a small proportion of cancer patients. Recent studies have shown that matrix metalloproteinases (MMPs) are highly associated with the microenvironment
Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression
Reggiani F, et al.
Cancer Research, 77(18), 5169-5182 (2017)
Hongxia Cai et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 25(6), 1448-1459 (2017-04-12)
Matrix metalloproteinase 9 (MMP-9) plays a beneficial role in the delayed phase of middle cerebral artery occlusion (MCAO). However, the mechanism is obscure. Here, we constructed hypoxia response element (HRE)-regulated MMP-9 to explore its effect on glial scars and neurogenesis in
Craig C Ulrich et al.
Biology of reproduction, 100(6), 1597-1604 (2019-04-06)
Matrix metalloproteinases 2 and 9 (MMP2/9) have previously been shown to be elevated in serum and amniotic fluid from women undergoing preterm birth. We performed experiments to determine the effects of MMP2/9 on uterine contraction and birth timing. Pregnant mice
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service